JAK2 V617F Mutation Analysis - Quantitative
Also known as: JAK2 V617F Quantitative Analysis
Use
The JAK2 V617F mutation is present in approximately 90% of polycythemia vera (PV) cases and approximately half of primary myelofibrosis (PMF) or essential thrombocythemia (ET). Quantitation of V617F is useful for monitoring myeloproliferative neoplasm (MPN) patients’ response to clinical treatment because mutational load correlates with disease course, making it a useful predictive marker.
Special Instructions
Test is DNA‑based. Extract & Hold – DNA service should be selected if specimen hold is desired. Sodium Heparin tubes are acceptable. Use a cold pack for transport (not in direct contact with specimen), ship same day when possible. New York State (NYS) clients must provide date and time of collection.
Limitations
Not provided.
New York Approved
Methodology
PCR‑based (qPCR)
Biomarkers
Result Turnaround Time
7 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
2 mL
Minimum Volume
Not provided
Container
EDTA tube